Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-B7-H3/CD28 bispecific antibody XmAb808

A bispecific antibody directed against the tumor-associated antigen (TAA) and immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and the co-stimulatory T-cell surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of anti-B7-H3/CD28 bispecific antibody XmAb808, this bispecific antibody binds to both B7-H3 on certain tumor cells and CD28 on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to B7-H3-expressing tumor cells, which may result in the CTL-mediated cell death of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.
Synonym:anti-B7-H3/anti-CD28 bispecific antibody XmAb808
B7-H3 x CD28 bispecific antibody XmAb808
Code name:XmAb 808
XmAb-808
XmAb808
Search NCI's Drug Dictionary